The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1152
March 17, 2003
View Complete Issue         Table of Contents 2019 
Montelukast (Singulair) for Allergic Rhinitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Montelukast (Singulair) for Allergic Rhinitis
March 17, 2003 (Issue: 1152)
Montelukast (Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma (Treatment Guidelines from The Medical Letter 2002; 1:11), has been approved by the FDA for treatment of seasonal allergic rhinitis in adults and children...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Montelukast (Singulair) for Allergic Rhinitis
Article code: 1152a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.